arrow
M

Marcel Wiesweg

university of duisburg essen
H指数:21
被引数:2,742

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event

肺癌一线/诱导治疗中的亚临床肺栓塞 - 一个持续存在的临床相关不良事件

2026-09-220
OAAI
PET/CT-Guided Management of Immune Checkpoint Blockade and Post-Treatment Multi-Modal Profiling in Long-Term Responders with Metastatic Lung Cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)

PET/CT引导下对转移性肺癌长期应答者的免疫检查点阻断管理及治疗后多模式分析——德国国家网络基因组医学肺癌项目(nNGM)

2025-12-300
OAAI
Long-term outcomes of preoperative nivolumab with or without relatlimab in patients with resectable non-small-cell lung cancer (NEOpredict-Lung)

可切除非小细胞肺癌患者术前纳武利尤单抗联合或不联合雷迪利单抗的长期结局(NEOpredict-Lung)

2025-12-050
PREAI
Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung Cancer

病理完全缓解预测III期非小细胞肺癌新辅助诱导化疗及放化疗后的长期生存率

2025-11-190
OAAI
[18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer

[18F]FDG-PET/CT在评估Ⅱ期-Ⅲ期小细胞肺癌诱导化疗及同期放化疗期间肿瘤反应动力学中的应用

2025-11-170
OAAI
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification

利用自动CT体成分分析杠杆化肌肉减少症指数,用于泛癌种预后分层。

2025-10-140
OA
Early Years, Advanced Disease: The Unmet Need in Young Adults with Non-Small Cell Lung Cancer

早年,晚期疾病:非小细胞肺癌年轻成年患者中的未满足需求

2025-09-240
OAAI
Treatment Sequences in BRAF-V600–Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy

BRAF-V600-Mutated NSCLC的治疗顺序: 一线靶向治疗与一线 (化疗) 免疫治疗

2025-05-080
OAAI
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

EGFR突变的非小细胞肺癌的小细胞转化: DLL3的表达和免疫检查点抑制剂或酪氨酸激酶抑制剂联合化疗的疗效

2024-12-010
OAAI
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations [Eur J Cancer 207 (2024) 114158]
2024-12-010
OAAI
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome

寡转移非小细胞肺癌: 局部和当代系统治疗方法对临床结果的影响

2024-09-254
OAAI
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
2024-08-012
OAAI
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial

nivolumab联合或不联合relatlimab新辅助治疗可切除的非小细胞肺癌: 一项随机2期试验

2024-04-3012
OAAI
Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies

未知原发癌的综合生物标志物诊断,以确定符合精确医疗治疗条件的患者

2024-03-012
OA
Theranostics with somatostatin receptor antagonists in SCLC: Correlation of 68Ga-SSO120 PET with
2024-01-010
OAAI